Compare RCKT & CYRX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | RCKT | CYRX |
|---|---|---|
| Founded | 1999 | 1999 |
| Country | United States | United States |
| Employees | 202 | 1100 |
| Industry | Biotechnology: Pharmaceutical Preparations | Biotechnology: Pharmaceutical Preparations |
| Sector | Health Care | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 503.8M | 421.6M |
| IPO Year | N/A | 2008 |
| Metric | RCKT | CYRX |
|---|---|---|
| Price | $4.72 | $7.84 |
| Analyst Decision | Buy | Strong Buy |
| Analyst Count | 14 | 9 |
| Target Price | ★ $29.65 | $12.94 |
| AVG Volume (30 Days) | ★ 2.8M | 380.4K |
| Earning Date | 01-01-0001 | 06-04-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ 156.22 |
| EPS | N/A | ★ 1.40 |
| Revenue | N/A | ★ $176,177,000.00 |
| Revenue This Year | N/A | $9.71 |
| Revenue Next Year | $97.68 | $9.56 |
| P/E Ratio | ★ N/A | $5.51 |
| Revenue Growth | ★ N/A | N/A |
| 52 Week Low | $2.19 | $4.63 |
| 52 Week High | $8.80 | $11.45 |
| Indicator | RCKT | CYRX |
|---|---|---|
| Relative Strength Index (RSI) | 57.08 | 38.13 |
| Support Level | $2.99 | $6.57 |
| Resistance Level | $5.34 | $9.32 |
| Average True Range (ATR) | 0.38 | 0.45 |
| MACD | 0.02 | -0.01 |
| Stochastic Oscillator | 48.25 | 15.43 |
Rocket Pharmaceuticals Inc is a late-stage biopharmaceutical company. It is focused on the development of gene therapies for rare and devastating pediatric diseases. The pipeline products of the company include RP-A501 for Danaon Disease, RP-L102 for Fanconi Anemia, RP-L201 for Leukocyte Adhesion, RP-L301 for Pyruvate Kinase Deficiency, and RP-L401 for Infantile Malignant Osteopetrosis. The Company has one reportable segment related to R&D and commercial readiness of its gene therapies.
CryoPort Inc is a leader serving the life sciences industry as a provider of integrated temperature-controlled supply chain solutions supporting the life sciences in the biopharma/pharma, animal health, and reproductive medicine markets. It operates in two reportable segments: Life Sciences Services and Life Sciences Products. Geographically the company operates in the Americas, Europe, the Middle East and Africa (EMEA), and Asia Pacific (APAC), generating a majority of its revenue from the Americas.